Press Release — for immediate release
September 14, 2005

Invitrogen and Fred Hutchinson Cancer Research Center Team on Cancer Screening

Invitrogen and the Fred Hutchinson Cancer Research Center announced they have entered into a multi-year collaborative research program for the development of diagnostics and screening tools for cancer. Under the collaboration, Invitrogen will use our expertise with the human proteome and proteomics-based approaches in combination with investigations by the lab of Sam Hanash, M.D., Ph.D., at the Hutchinson Center. Invitrogen will utilize a variety of our proteomics technologies including our flagship ProtoArray™ protein microarrays and extensive protein and antibody collections. Invitrogen will also be able to license technologies produced as a result of the collaboration. Other terms of the collaboration were not disclosed.

"We are honored to be working alongside pre-eminent scientists such as Dr. Hanash," said Invitrogen Chairman and CEO, Gregory T. Lucier. "At Invitrogen we have developed and applied a comprehensive biotechnology platform to the challenge of accelerating drug discovery and disease research. This collaboration is another important step in our efforts to support patient-specific research."

Earlier detection of cancer allows for potentially higher cure rates. The collaboration is aimed at producing enabling, industry-changing technology that will change the way diseases are diagnosed and treated. Additionally, technology developed from the partnership has the potential to greatly accelerate proteomics-based approaches for all biomedical research—one of the most crucial areas of study today.

"The Fred Hutchinson Cancer Research Center is focused on preventing, diagnosing and treating cancer and other debilitating disease," explained Hanash. "We are excited to work with an organization like Invitrogen to re-think cancer research. We believe this collaboration can push the boundaries of current cancer detection."

Invitrogen's proteomics capabilities span a broad range of applications including protein expression, separation, characterization and target screening. The collaborative effort is highlighted by Invitrogen's ProtoArray—a functional microarray used to measure protein interactions that could prove key to better therapeutic monitoring, and cures with far fewer drug side-effects. Currently, the ProtoArray contains more than 5,000 unique human proteins focused on key drug target families. Invitrogen has continued development of the array content with an eventual goal of capturing every significant human protein on the chips.

In 2004 Invitrogen announced a partnership with Mayo Clinic around the discovery of unique cancer biomarkers using our drug discovery technology portfolio. Together these collaborations demonstrate a broad approach to oncology research utilizing different tools to solve unique challenges at each organization.

"We believe that as our understanding of disease at a molecular level advances, early screening systems will play an important role in optimizing therapy," concluded Lucier. "We are hopeful screening technologies from our partnership with the Hutchinson Center will allow physicians in the future to quickly diagnose disease and determine treatment options for patients before they even know they are sick."

For more information about Fred Hutchinson Cancer Research Center go to www.fhcrc.org.